China Insulin Glargine Market Outlook to 2018

1
Investigation Report on China Insulin Glargine
Market, 2009-2018byChina Research and
Intelligence

• Explore all reports for Life Sciences market
• _at_ http//www.chinamarketresearchreports.com/cat/li
  fe-sciences.html.

2
Investigation Report on China Insulin Glargine
Market, 2009-2018

• With the improvement of people's living standard
  and changing of lifestyles, as well as deepening
  of the aging of society, prevalence rate of
  diabetes keeps rising, making it the third most
  threatening chronic disease to human health after
  tumor and cardiovascular disease. Its risk to
  disable or kill has become a heavy burden on
  individuals, families, society and governments.
• According to statistics from IDF (International
  Diabetes Federation), the global prevalence rate
  of diabetes among adults aged 20 to 79 was 8.3
  in 2013. The number of diabetes patients has
  reached 382 million, of which 80 are from medium
  and low income countries where it is still rising
  rapidly.
• Inquire for a discount on this report _at_
  http//www.chinamarketresearchreports.com/contacts
  /inquire-before-buy.php?name114725 .

3
Investigation Report on China Insulin Glargine
Market, 2009-2018

• It is estimated that by 2035 there will be nearly
  592 million people worldwide suffering from
  diabetes. In the evaluation of diabetes
  incidence and its trend among various countries
  and regions, China ranked the first with 98.4
  million diabetes patients in 2013, followed by
  India (65.1 million), the U.S.A. (24.4 million),
  Brazil (11.9 million) and Russia (10.9 million).
  IDF estimates that the number of diabetes
  patients in China will reach 143 million by 2035,
  which will still be the highest worldwide while
  that in the U.S.A. will merely reach 29.7
  million. Rapid growth of diabetes in China and
  other developing countries has become an
  extraordinarily serious burden for these
  countries' social and economic development.
• Insulin glargine is the first long acting insulin
  analogue produced through recombinant DNA
  technology. It was approved for use by FDA (Food
  and Drug Administration) in April 2000 and EMEA
  (European Medicines Evaluation Agency) in June
  2000. As there is no apparent peak in long term
  use of insulin glargine, it has become the most
  widely used insulin in the United States.
• Complete report available _at_ http//www.chinamarket
  researchreports.com/114725.html .